Arrowhead Pharmaceuticals, Inc.
Moat Score — Arrowhead Pharmaceuticals, Inc.
Total Moat Score
12 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Arrowhead's proprietary TRiM tissue-targeted RNAi delivery platform and its growing patent estate around GalNAc-conjugate and lung-delivery chemistries represent substantial, defensible intellectual property built over many years of platform development. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a company just transitioning to commercial stage, Arrowhead does not yet have a demonstrated manufacturing or commercial scale cost advantage versus larger, more established RNAi leader Alnylam Pharmaceuticals. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | Arrowhead's approved therapy for severe hypertriglyceridemia addresses a rare, high-unmet-need condition with limited alternative treatments, supporting meaningful specialty-drug pricing power, though ultimate power will be tested as the product scales commercially. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in RNAi drug development or delivery technology. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once physicians and patients establish a treatment routine with an approved RNAi therapy (often infrequent dosing), there is some treatment inertia, but patients could switch to alternative therapies including Ionis's antisense approach if warranted. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Building a validated, tissue-targeted RNAi delivery platform requires years of R&D investment that few companies have successfully replicated, giving Arrowhead a meaningful head start over new entrants, even as it still trails market leader Alnylam in overall scale and commercial infrastructure. |